Arana begins Phase II
Thursday, 11 December, 2008
Arana Therapeutics has begun its Phase II trial of its domain antibody ART621 for rheumatoid arthritis.
The trial, which will recruit 200 patients, will held in eight countries, including Australia, the US and India.
It will test the efficacy of ART621 in rheumatoid arthritis and will compare three doses of ART621 with a placebo in patients also taking methotrexate, a common anti-metabolite that inhibits the metabolism of folic acid.
Results are due in mid-2010.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
